The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MDP, MGNX and CVET
NEW YORK, NY / ACCESSWIRE / November 5, 2019 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Meredith Corporation (MDP)
Investors Affected : January 31, 2018 - September 5, 2019
A class action has commenced on behalf of certain shareholders in Meredith Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Time, Inc. acquisition was not as profitable as the Company had claimed; (2) the Company would incur additional costs for strategic investments to improve the Time business; (3) as a result, the Company's earnings would be materially and adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Shareholders may find more information at https://securitiesclasslaw.com/securities/meredith-corporation-loss-submission-form/?id=4173&from=1
MacroGenics, Inc. (MGNX)
Investors Affected : February 6, 2019 - June 3, 2019
A class action has commenced on behalf of certain shareholders in MacroGenics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.
Shareholders may find more information at https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form/?id=4173&from=1
Covetrus, Inc. (CVET)
Investors Affected : February 8, 2019 - August 12, 2019
A class action has commenced on behalf of certain shareholders in Covetrus, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had overstated its capabilities with regard to inventory management and supply chain services; (ii) Covetrus had understated the costs of the integration of Henry Schein's Animal Health Business and VFC, including the timing and nature of those costs; (iii) Covetrus had understated its separation costs from Henry Schein; and (iv) the Company understated the impact on earnings from online competition and alternative distribution channels as well as the impact of the loss of a large customer in North America just prior to the Company's separation from Henry Schein.
Shareholders may find more information at https://securitiesclasslaw.com/securities/covetrus-inc-loss-submission-form/?id=4173&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com:
https://www.accesswire.com/565347/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-MDP-MGNX-and-CVET
